



## **Webcast Alert: Aastrom to Host Investor Conference Call on Critical Limb Ischemia and Related Clinical Development Progress**

**Ann Arbor, Michigan, May 3, 2010 (3:20 pm ET)** -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following webcast:

Investor conference call to present an update on clinical development efforts related to critical limb ischemia (CLI).

**What:** The event will also feature a Q&A session with Anthony J. Comerota, MD, FACS, FACC, director of the Jobst Vascular Center in Toledo, Ohio.

**When:** Monday, May 10, 2010 @ 1:00 pm (ET)

**Where:** <http://www.investorcalendar.com/IC/CEPage.asp?ID=158215>

- For live Internet access, simply log on to the web at the address above.
- For phone access, interested parties should call toll-free (877) 407-9210 before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8049.
- To download the podcast, simply log on to the web at the address above.

**How:**

If you are unable to participate during the live call, the webcast will be available for replay at <http://www.investorcalendar.com/> until August 10, 2010. Through May 24, 2010, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the Account # is: 286, and the Conference ID# is: 350255.

### **About Aastrom Biosciences**

Aastrom Biosciences is developing autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies using a patient's own bone marrow that can be delivered directly to damaged tissues. Aastrom has advanced this technology into late-stage clinical development and is conducting two Phase 2 clinical trials to treat dilated cardiomyopathy and a Phase 2b clinical trial to treat critical limb ischemia. For more information, please visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).

### **Media contact**

Stephen Zoegall  
Berry & Company  
212 253-8881  
[szoegall@berrypr.com](mailto:szoegall@berrypr.com)

### **Investor Contact**

Kimberli O'Meara  
Aastrom Biosciences  
734 930-5777  
[ir@aastrom.com](mailto:ir@aastrom.com)